Topics

Companies Related to "Dietary vulnerability found cancer cells with mutated spliceosomes" [Most Relevant Company Matches] - Page: 2 RSS

07:14 EST 16th December 2019 | BioPortfolio

Here are the most relevant search results for "Dietary vulnerability found cancer cells with mutated spliceosomes" found in our extensive corporate database of over 50,000 company records.

Showing "Dietary vulnerability found cancer cells with mutated spliceosomes" Companies 26–50 of 4,000+

Relevant

Epic Sciences, Inc.

Epic Sciences, Inc. (www.epicsciences.com) is a privately held diagnostics company committed to improving cancer management by providing easily accessible and real-time biopsy material to guide personalized medicine. Epic is founded on a powerful platform to identify and characterize rare cells including circulating tumor cells (“CTCs”). Epic is ...


Pro-Pharmaceuticals

Pro-Pharmaceuticals Inc. is a research leader in developing a new generation of Glyco-upgrade™ oncologic drugs. We target sugar-specific binding sites found on cancer cells using carbohydrate technology with the goal of improving efficacy and reducing toxicity of some of the proven, commonly used anti-cancer drugs.Two platforms of technologies have been identified by Pro- Pharmaceuticals. The fi...

Immunicon Corporation

Immunicon is developing and commercializing diagnostic and research products for rare cell analysis and molecular research, with an initial focus on cancer. Our instruments and reagents are used to capture, count and characterize rare cells including circulating tumor cells (CTCs) in cancer patients or circulating endothelial cells (CECs), which are elevated in a variety of diseases. Our goal is t...


Fate Therapeutics Inc.

Founded in 2007 on the leading stem cell and developmental biology research, Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation’s research hotbeds (Boston, San Francisco, San Diego and Seattle) who have demonstrated the potential to create and modulate st...

Endocyte

Endocyte is developing a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases. Current non-targeted drugs are usually toxic to normal healthy cells causing serious side effects. These side effects can be life-threatening which leads to suboptimal dosing. Receptor-targeted therapeutics can be more effective because they can be targete...

Heat Biologics, Inc.

Heat Biologics (www.heatbio.com) (“Heat”) is a clinical-stage company immunotherapy company focused on developing its novel off-the-shelf “ImPACT” (Immune Pan-Antigen Cytotoxic Therapy) therapeutic vaccines to combat a wide range of cancers and other diseases. Heat’s ImPACT Therapy effectively reprograms tumor cells to “pump o...

Tizona Therapeutics, Inc.

Tizona Therapeutics, Inc., is a privately held immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune disorders. A healthy immune system integrates information from pro-inflammatory and anti-inflammatory cells that regulate the immune system’s function. In cancer, tumor cells evade recognition by c...

ActoKine Therapeutics

Cancer therapy using cytotoxic drugs or radiation has negative side effects on normal cells. To date, the pharmaceutical industry has not been able to produce a drug that can provide the dual functions of protecting normal cells while sensitizing tumor cells to cancer therapy. With consultation and guidance from industry experts, ActoKine will collaborate with international drug companies and inst...

Matritech

Matritech, Inc. develops, manufactures and markets innovative cancer diagnostic products based on its proprietarynuclear matrix protein ("NMP") technology. The nuclear matrix, a three dimensional protein framework within the nucleus of cells, plays a fundamental role in determining cell type by physically organizing the contents of the nucleus, including DNA. The Company has demonstrated that th...

Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better treatments and cures for prostate cancer. Founded in 1993, the PCF has raised nearly $400 million and provided funding to more than 1,500 researchers at nearly 200 institutions wor...

Provectus Biopharmaceuticals, Inc.

Provectus Biopharmaceuticals specializes in developing oncology and dermatology therapies. Its novel oncology drug PV-10 is designed to selectively target and destroy cancer cells without harming surrounding healthy tissue, significantly reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver....

INSCATECH

INSCATECH is a Food Fraud detection and prevention company. The only company of its kind, INSCATECH has established a solid reputation in the food industry as both a pioneer and the sole provider of food fraud intelligence investigations, forensically based vulnerability assessments, supplier qualification examinations, validated supply chain mapping,Â...

Lion Biotechnologies, Inc.

Lion Biotechnologies, Inc., formerly Genesis Biopharma, Inc., is engaged in the development of T-cells and engineered T-cells for the treatment of various cancers. The company's lead product candidate is a ready-to-infuse autologous T-cell therapy utilizing tumor-infiltrating lymphocytes (TILs) for the treatment of patients with Stage IV metastatic melanom...

The Prostate Cancer Foundation

The Prostate Cancer Foundation is the world’s largest philanthropic source of support for prostate cancer research focused on discovering better treatments and a cure for prostate cancer at every stage of diagnosis. Founded in 1993, the PCF has raised more than $370 million and provided funding to more than 1,500 research projects at nearly 200 instit...

Third Coast Therapeutics

Third Coast Therapeutics is a biotechnology company dedicated to developing orally active, small-molecule drugs that target the spread of cancer cells. Metastasis is estimated to cause 90 percent of cancer deaths. There are currently no approved drugs targeting this process. Third Coast’s lead candidate, 3crx98, is specifically designed to inhibit the movement of cancer cells without toxic s...

DNAtrix Inc.

DNAtrix is a company developing modified oncolytic viruses for the treatment of the most aggressive forms of cancer. Since viruses are already efficient at killing cells, scientists have harnessed this ability by modifying a common cold virus so that it targets and selectively kills cancer cells. DNAtrix is a privately held company with offices located in ...

Abalos Therapeutics

Abalos Therapeutics has harnessed the unique immune stimulation of the arenavirus to develop a novel anti-cancer approach that provides the full breadth of the immune system’s power specifically against cancer cells. Through viral replication within cancer cells, Abalos’ arenavirus-based drug candidates are designed to awake precise innate and adaptive immune responses and activate all ...

Surface Oncology, Inc.

Surface is creating the next generation of immunotherapies for cancer. To fully unlock the potential of cancer immunotherapy, Surface is targeting a broader set of immune processes by which cancer cells evade immune recognition and attack. Our programs are built upon emerging, proprietary insights about how to improve the immune system’s recognition a...

Coley Pharmaceutical Group

Our proprietary TLR Therapeutics™ act by stimulating a specific class of targets, called Toll-like receptors, or TLRs, found in and on immune system cells which, in turn, direct the immune system to fight disease.Coley’s pipeline of TLR Therapeutics includes four clinical-stage products targeting cancer, viral diseases, asthma and allergy:

Agilvax

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critic...

Agilvax, Inc.

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critic...

Targeted Diagnostics & Therapeutics, Inc

TDT has emerged as a leader in the development of innovative molecular diagnostics and therapeutics that can improve the quality of life of patients with colorectal cancer and gastrointestinal malignancies. Focused on innovative research and cutting edge technology, TDT has developed highly specific tests to detect colorectal cancer cells in lymph nodes from patients who have undergone surgical st...

Aastrom Biosciences Incorporated

Aastrom Biosciences, Inc. (Nasdaq: ASTM) is developing automated cell therapy systems designed to enable on-site cell production for therapeutic procedures using living cells in patients treated for cancer and other diseases and cells used in the restoration of normal tissues. The Company has received approval to affix the CE Mark to the various components of the AastromReplicell™ System, the SC...

Spirogen and BioAtla

Spirogen Limited (“Spirogen”) was founded in 2001 as a spin-out from several institutions including University College, London. Since that time, it has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (“PBD’s”), DNA minor groove binding agents, which bind and cross-link specific s...

AC Vaccine technology

The AC Vaccine technology is a therapuetic treatment based on the concept of haptenization. This idea has a long history, beginning with the work of the immunologist and Nobel laureate Karl Landsteiner in the 1920’s. He and other scientists showed in animal models that attaching a small chemical (a hapten) to a protein allowed that protein to be recognized by the immune system even if the anim...


More From BioPortfolio on "Dietary vulnerability found cancer cells with mutated spliceosomes"

Quick Search

Corporate Database Quicklinks